RxDoctor Payments Data

Sunil Adwani, MD

Internal Medicine · Manhattan Beach, CANPI 1285043539

Payments from drug & device makers

$4,900in general payments, 2019–2025

Across 29 payments — averaging $168.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$4K
  • Boston Scientific$162
  • Abbott$134
  • Inspire Medical Systems, Inc.$115
  • Exact Sciences$48
  • AbbVie$33
  • plus $33 from 3 others

What the payments were for

  • Consulting fees$2,10043%
  • Travel & lodging$1,94740%
  • Food & beverage$84217%
  • Education$120%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,900 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$89,121
Medicare patients
348
Services billed
1,416

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin67$90,346
OzempicSemaglutide50$65,049
EliquisApixaban34$51,717
RybelsusSemaglutide24$45,308
MounjaroTirzepatide23$30,995
FarxigaDapagliflozin Propanediol24$29,825
JanuviaSitagliptin Phosphate17$28,220
XareltoRivaroxaban16$23,758
EntrestoSacubitril/Valsartan20$22,296
Praluent PenAlirocumab11$13,936
MyrbetriqMirabegron20$11,085
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$9,523
Repatha SureclickEvolocumab13$6,951
SymbicortBudesonide/Formoterol Fumarate12$6,303
Breo ElliptaFluticasone/Vilanterol13$5,974

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$12$30,99523 claims
AbbVieSynthroid$33$1,32516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Manhattan Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →